Business
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update
SOUTH SAN FRANCISCO, Calif., August 07, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 first quarter ended June 30, 2025, and provided a corporate update.
About this update from Vistagen Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":542,"url":"https://media.zenfs.com/en/business-wire.com/91696125c90e0289b482e88a4d386448"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nKckV7RlOj1ondXMsaslkw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/91696125c90e0289b482e88a4d386448","width":960,"height":260},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/d_xAVQxjyUhup3CoWZpyXg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/91696125c90e0289b482e88a4d386448","width":1200,"height":325}},"lazy":false},{"type":"text","content":"Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of 2025","length":143,"tagName":"p","attribs":{}},{"type":"text","content":"PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026","length":75,"tagName":"p","attribs":{}},{"type":"text","content":"Vistagen continues to advance diverse intranasal pherine pipeline targeting treatments in psychiatry, women’s health, and cancer supportive care","length":144,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., August 07, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 first quarter ended June 30, 2025, and provided a corporate update.","length":410,"tagName":"p"},{"type":"text","content":""We had another productive quarter, advancing key programs across our pipeline," said Shawn Singh, President and Chief Executive Officer of Vistagen. "Our lead program, fasedienol, for acute treatment of social anxiety disorder, continues to progress, with topline results from our PALISADE-3 Phase 3 trial anticipated later this year, and topline results from our PALISADE-4 Phase 3 trial expected in the first half of 2026. With no FDA-approved acute treatment, we remain optimistic about fasedienol’s potential to impact the lives of over 30 million U.S. adults affected by ...